Latest Stock Buy or Sell? Make More Informed Decisions!
Today, Eric Nuttall and The Panic-Proof Portfolio (Stockchase Research) commented about whether GGAL-Q, VEON-Q, CNR-T, ASO-Q, SBS-N, MCY-N, RPRX-Q, ARX-T, ATH-T, MEG-T, KEL-T, SU-T, DVN-N, AAV-T, CVE-T, LCX-X, HWX-T, PD-T, BTE-T, VRN-T, CHRD-Q, NVA-T, FRU-T, CNQ-T, CEU-T, TVE-T, PXT-T are stocks to buy or sell.
- Page 2/2
- Next Page
They underperformed a lot last year, but have been righting the ship after disappointing quarters. Has deep value, trading at 4x, a 15% free cash flow yield, though worried about inventory depth in the Permian. He must prefers Canadian oil sand companies (solid balance sheet, long inventories, execution, share buybacks).
One of his largest holdings. It has sold off from tariff worries, just hitting a one-year low. They have 35 years of stay-flat inventory. Over 5 years, will grow production 25% while buying back half their shares as they pay a dividend. At $70, will trade at 4x cash flow and 13% free cash flow yield. At $80, they could buyback 80% of shares over 5 years. Is way oversold. Targets $30 in a year.
(Analysts’ price target is $31.25)Buy any dip. They will modestly grow production over 5 years and buy 68% of shares at the current oil price; at $80 they could almost privatize. At $70 oil in 5 years, they will free cash flow at the current share price. Has 50 years of stay-flat inventory. At flat oil, will go from 3.9x cash flow this year, 3.2x in 2026 and 0.3x in 2029.
(Analysts’ price target is $6.42)
We reiterate RPRX as a TOP PICK. This unique pharma company has investments in 35 jointly developed royalty products, with the largest pharma companies and has several new joint products in development. It trades at 17x earnings, 2.1x book and supports a 12% ROE. We recommend trailing up the stop (from $26) to $29, looking to achieve $41 — upside potential of 25%. Yield 2.6%
(Analysts’ price target is $41.00)We reiterate MCY, a provider of insurance in California as a TOP PICK. The company recently reported the impact from the LA fires will not be as bad as feared and that liquidity remains strong. It trades at 9x earnings, 1.6x book and supports a robust 26% ROE. We recommend trailing up the stop (from $35) to $40, looking to achieve $69 — upside potential over 25%. Yield 2.3%
(Analysts’ price target is $80.00)We reiterate SBS, Brazil’s water treatment and sewage management utility as a TOP PICK. Aside from offering global diversification, it operates in a conservative space. It trades at 15x earnings, 1.6x book and supports a ROE of 27%. We continue to recommend a stop at $14, looking to achieve $21 — upside potential over 25%. Yield 3.1%
(Analysts’ price target is $20.79)Our PAST TOP PICK with ASO has triggered its stop at $47. To remain disciplined, we recommend covering the position at this time. When combined with our previous guidance, this will result in a net investment loss of 10%.
Our PAST TOP PICK with VEON has triggered its stop at $40. To remain disciplined, we recommend covering the position at this time. When combined with our previous guidance, this will result in a net investment gain of 16%.
One of the worst energy names. The CEO and board did one of the word acquisitions in history. When the market wanted natural gas, they added liquids exposure. Are the worst-performing nat gas stock in North America. No upside. An activist has put members on the board.